In vitro, the resveratrol analogue HS-1793 was shown to inhibit hypoxia-induced HIF-1α expression in breast cancer cell lines (MCF-7 and MDA-MB-23) more than normal resveratrol, acting at a post-transcriptional level [50]. The gene discussed is HIF1A; the disease is breast carcinoma.